Home Tags Pyrrolobenzodiazepine

Tag: pyrrolobenzodiazepine

Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...

Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...

Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...

Innate Pharma Confirms Securing Investment to Develop Novel ADC

The French biotechnology company Innate Pharma, which focuses on the discovery as well as the development and commercialization of novel therapeutic antibodies-based therapeutics to...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...

First Patient Dosed in Phase Ib Clinical Trial of Camidanlumab Tesirine...

A first patient has been dosed in Phase Ib clinical trial of camidanlumab tesirine, also know ADCT-301, a proprietary antibody-drug conjugate or ADC being...

Study Evaluates Pyrrolobenzodiazepine (PBD)-dimers Containing Disulfide-based Prodrugs as Payloads for Antibody-Drug...

A number of cytotoxic pyrrolobenzodiazepine (PBD) monomers containing various disulfide-based prodrugs were evaluated for their ability to undergo activation (disulfide cleavage) in vitro in...

Anti-CLL-1 ADC May Offer Effective and Safe Treatment Options for Patients...

Over the last 40 years treatment of acute myeloid leukemia or AML has not significantly changed.Today, the standard of care for AML is treatment...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...

Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...

First Clinical Data from ADCT-402 Demonstrates Encouraging Antitumor Activity in r/r...

The first clinical data from an ongoing Phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma has been...

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...